Efficiency and safety of direct oral anticoagulants in onco-associated venous thromboembolic complications: meta-analysis
- Authors: Petrov V.I.1, Akinchits A.N.1, Shatalova O.V.1, Gorbatenko V.S.1, Gerasimenko A.S.1
-
Affiliations:
- Volgograd State Medical University
- Issue: Vol 26, No 6 (2020)
- Pages: 402-411
- Section: Clinical pharmacology and pharmaceuticals
- URL: https://bakhtiniada.ru/0869-2106/article/view/65034
- DOI: https://doi.org/10.17816/0869-2106-2020-26-6-402-411
- ID: 65034
Cite item
Abstract
The work aimed to analyze the efficiency and safety of direct oral anticoagulants in treating onco-associated venous thromboembolic complications.
Materials and methods. A meta-analysis of randomized controlled trials was performed in accordance with the guidelines “Preferred reporting parameters for systematic reviews and meta-analyses.”
Results. Data from four randomized controlled trials were used to perform the meta-analysis. Direct oral anticoagulants reduce the relative risk of recurrent venous thromboembolic complications compared with dalteparin by 38% (relative ratio [RR]=0.62; 95% confidence interval [CI] [0.43–0.91]; p=0.01) and reduce statistically significantly the risk of deep vein thrombosis by 40% (RR=0.60; 95% CI [0.40–0.90]; p=0.01). In the effectiveness of prevention of repeated pulmonary embolism, the compared technologies are comparable (RR=0.89; 95% CI [0.52–1.51]; p=0.66). A safety meta-analysis suggests that direct oral anticoagulants are comparable in safety compared with dalteparin, in terms of major bleeding incidences (RR=1.33; 95% CI [0.84–2.11]; p=0.23) and in relation to gastrointestinal bleeding development (RR=1.91; 95% CI [0.96–3.82]; p=0.07). Direct oral anticoagulants increased the incidence of clinically significant minor bleeding (RR=1.58; 95% CI [1.11–2.24]; p=0.01).
Full Text
##article.viewOnOriginalSite##About the authors
Vladimir I. Petrov
Volgograd State Medical University
Email: shov_med@mail.ru
MD, PhD, DSc, Professor, Academician of RAS
Russian Federation, 400131, VolgogradAleksandr N. Akinchits
Volgograd State Medical University
Email: shov_med@mail.ru
MD, PhD, DSc
Russian Federation, 400131, VolgogradOlga V. Shatalova
Volgograd State Medical University
Author for correspondence.
Email: shov_med@mail.ru
ORCID iD: 0000-0002-7311-4549
MD, PhD, DSc, Professor
Russian Federation, 400131, VolgogradVladislav S. Gorbatenko
Volgograd State Medical University
Email: shov_med@mail.ru
ORCID iD: 0000-0002-6565-2566
MD, PhD
Russian Federation, 400131, VolgogradAnastasiya S. Gerasimenko
Volgograd State Medical University
Email: shov_med@mail.ru
ORCID iD: 0000-0002-7957-3770
Russian Federation, 400131, Volgograd
References
- Ashrani AA, Marks RS, Petterson TM, Bailey KR, Melton LJ 3rd, Heit JA. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;123(25):3972–3978. doi: 10.1182/blood-2014-01-549733.
- Barsam SJ, Patel R, Arya R. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. Br J Haematol. 2013;161(6):764–777. doi: 10.1111/bjh.12314.
- Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164:S112–S118. doi: 10.1016/j.thromres.2018.01.028.
- Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–1723. doi: 10.1182/blood-2013-04-460121.
- Khorana AA, Francis CW. Risk prediction of cancer-associated thrombosis: appraising the first decade and developing the future. Thromb Res. 2018;164 Suppl 1:S70–S76. doi: 10.1016/j.thromres.2018.01.036.
- Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–464. doi: 10.1001/archinte.166.4.458.
- Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–634. doi: 10.1111/j.1538-7836.2007.02374.x.
- Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–377. doi: 10.1097/SLA.0000000000000378.
- Watson HG, Keeling DM, Laffan M, Tait RC, Makris M. British Committee for Standards in H. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015;170(5):640–648. doi: 10.1111/bjh.13556.
- Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res. 2020;S1931-5244(20)30164-X. doi: 10.1016/j.trsl.2020.06.012.
- Monreal M, Falgá C, Valdés M, Suárez C, Gabriel F, Tolosa C, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2006;4(9):1950–1956. doi: 10.1111/j.1538-7836.2006.02082.x.
- Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. N Engl J Med. 2003;349(2):146–153. doi: 10.1056/NEJMoa025313.
- Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729–1735. doi: 10.1001/archinte.162.15.1729.
- Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J; ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12(4):389–396. doi: 10.1177/1076029606293692.
- Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062–1072. doi: 10.1016/j.amjmed.2006.02.022.
- Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs Warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677–686. doi: 10.1001/jama.2015.9243.
- Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;6:CD006650. doi: 10.1002/14651858.CD006650.pub5.
- Petrov VI, Shatalova OV, Gorbatenko BS. Efficacy and safety of new oral anticoagulants in patients with venous thromboembolic complications: a meta-analysis. Ratsional'naya farmakoterapiya v kardiologii. 2016;(1):31–39. (In Russ). doi: 10.20996/1819-6446-2016-12-1-31-39. .
- Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023. doi: 10.1200/jco.2018.78.8034.
- Marshall A, Levine M, Hill C, Hale D, Thirlwall J, Wilkie V, et al. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m). J Thromb Haemost. 2020;18(4):905–915. doi: 10.1111/jth.14752.
- McBane RD. 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–421. doi: 10.1111/jth.14662.
- Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607. doi: 10.1056/NEJMoa1915103.
- Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624. doi: 10.1056/NEJMoa1711948.
- Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;(3):123–130. doi: 10.1371/journal.pmed.1000097.
- Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;(127):820–826. doi: 10.7326/0003-4819-127-9-199711010-00008.
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;(22):719–748. doi: 10.1093/jnci/22.4.719.
Supplementary files
